Published by ChinaMNC ยท Diebu
US Adds Three Chinese Entities to Xinjiang-Linked List: What Foreign Founders Operating in China Should Know
China's Ministry of Commerce responds to the US addition of three Chinese entities to the so-called Uyghur Forced Labor Prevention Act entity list, rejecting the measures and warning of countermeasures. A practical briefing for foreign founders on compliance and operational risk in China.
What Happened
On October 28, US Eastern Time, the US Department of Homeland Security announced that three additional Chinese entities would be placed on the entity list tied to the so-called Uyghur Forced Labor Prevention Act. China's Ministry of Commerce (MOFCOM) spokesperson responded to a reporter's question on the matter, and the ministry's news office published the exchange on October 29.
For foreign founders registering or running a company in China, the exchange is worth reading closely. It signals how Beijing frames US entity-list actions and what companies may expect in terms of official rhetoric and potential countermeasures.
China's Position in Brief
The spokesperson said China has noted the development. According to the response, forced labor does not exist in China; people of all ethnic groups in Xinjiang enjoy free and equal employment, and their labor rights are effectively protected in accordance with the law. The spokesperson described the US measures as lacking any factual basis and characterized Washington's continued use of human rights themes as a cover for unilateral protectionism and bullying. China strongly condemned and firmly opposed the move, according to the statement.
Prior Listings and Countermeasures
The spokesperson noted that the US had recently added a large number of Chinese entities to the so-called Xinjiang-related entity list. China said it lodged solemn representations with the US side and firmly took countermeasures. According to the response, the US did not change course and, despite China's firm opposition, imposed further sanctions, this time adding Chinese biopharmaceutical technology enterprises to a sanctions list.
Characterization of the US Measures
The spokesperson said the US listing practice runs counter to the consensus reached by the heads of state of the two countries, seriously undermines the stability of China-US economic and trade relations, and goes against the spirit of humanitarianism. The statement called on the US to immediately stop political manipulation and smear attacks and to stop the unreasonable suppression of Chinese enterprises. China said it will take necessary measures to firmly safeguard its own interests.
Why This Matters for Foreign Founders in China
Entity-list actions are not only a bilateral diplomatic issue; they can affect supply chains, banking relationships, and compliance reviews for companies operating in China. Foreign founders should treat this development as a prompt to review their own exposure rather than as background noise.
- Supply chain screening: If your China-registered company sources from or sells to entities named on US lists, check whether your contracts, payment channels, or logistics partners could be affected.
- Banking and payments: Cross-border payments involving listed parties can trigger additional compliance checks. Keep documentation of the nature of each transaction.
- Countermeasure risk: China has said it will take necessary measures in response to US listings. Foreign-invested companies should monitor official announcements and avoid relying on a single legal or compliance interpretation.
- Sector sensitivity: The latest US action targeted biopharmaceutical technology enterprises. Founders in life sciences, advanced manufacturing, and technology sectors should pay particular attention to how listing actions evolve.
Practical Steps for Founders
1. Map Your Exposure
Identify any counterparties, investors, or suppliers that appear on US restricted-party lists, including the Xinjiang-related entity list. Document the results of your screening.
2. Keep Contracts Flexible
Review force majeure, compliance, and termination clauses. If a counterparty is listed, you may need to pause or restructure the relationship on short notice.
3. Maintain Clear Records
Keep records showing that your China entity operates independently and complies with Chinese law. Clear corporate governance and labor documentation are useful in any compliance review.
4. Follow Official Channels
MOFCOM publishes spokesperson statements and notices on its website. For regulatory changes affecting foreign investment, follow MOFCOM and other official sources rather than unverified reports.
5. Seek Local Advice
China's regulatory environment can change quickly. Work with qualified local counsel and your registered agent to interpret how new measures apply to your specific business.
What the Statement Does Not Say
The MOFCOM response does not name the three entities, does not specify which biopharmaceutical enterprises were listed, and does not detail the countermeasures China has taken or will take. Founders should not assume details beyond the official text. The statement is a diplomatic response, not a regulatory notice, and it does not set out new compliance obligations for foreign-invested companies.
Outlook
The exchange reflects continued tension over US entity-list designations and China's stated readiness to respond. For foreign founders, the practical takeaway is to build compliance resilience: know your counterparties, keep documentation, and monitor official announcements. China's market remains open to foreign investment, but operating successfully requires attention to both Chinese regulations and extraterritorial measures that may affect your business partners.
This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.
Need help registering or operating a company in China? Foreign founders can contact ChinaMNC on WhatsApp or WeChat at +86 153 1898 8535 for practical support with company registration, compliance, and ongoing operations in China.